Trajenta Duo 2.5/1000mg

Manufacturer
Boehringer Ingelheim
 
Contents
 Linagliptin 2.5 mg, metformin HCl 1,000 mg
 
Indication
Treatment of type 2 diabetes mellitus: Adjunct to diet & exercise to improve glycemic control in adult patients when treatment w/ both linagliptin & metformin is appropriate; in combination w/ a sulphonylurea, adjunct to diet & exercise in adult patients inadequately controlled on the maximal tolerated dose of metformin & sulphonylurea; in combination with insulin, adjunct to diet & exercise to improve glycaemic control in adult patients when insulin & metformin alone do not provide adequate glycaemic control. 
 
Instruction
Treatment of type 2 DM: Adjunct to diet & exercise to improve glycemic control in adult patients when treatment w/ both linagliptin & metformin is appropriate; in combination w/ a sulphonylurea, adjunct to diet & exercise in adult patients inadequately controlled on the maximal tolerated dose of metformin & sulphonylurea; in combination w/ insulin, adjunct to diet & exercise to improve glycaemic control in adult patients when insulin & metformin alone do not provide adequate glycaemic control. 
 
Drug interaction
Linagliptin: Increased AUC & C_max w/ ritonavir. Decreased steady-state AUC & C_max w/ rifampicin. Increased AUC & C_max of simvastatin. Metformin: Glucocorticoids (given by systemic & local routes), β₂-agonists & diuretics have intrinsic hyperglycaemic activity. Increased risk of lactic acidosis w/ alcohol intoxication; cimetidine, IV administration of iodinated contrast agents.